Chemistry World and Notch Communications welcome you to our sixth special collection of content focusing on the future of the pharmaceutical and healthcare industries. Collaboration across the sciences as well as digitisation and patient-specific therapies come together to bring us the treatments of tomorrow.
2019-11-18T09:30:00+00:00By Peter Brown and Adam Brownsell
It’s an exciting time in this challenging, yet ever-evolving, field
Sponsored by Waters Corporation, By Debbie Francis
Ion mobility spectrometry is transforming the field of biomolecule research, with Waters technology at the forefront of this vital analytical innovation
Sponsored by Nanoform, By Niklas Sandler
Drug particle engineering is set to revolutionise medicine and provide solutions to the world’s biggest healthcare challenges. Scientific innovator Nanoform is a vital part of that movement. Here’s why
Sponsored by CPI, By Dave Tudor
Scientific and digital collaboration is key to maintaining the UK’s esteemed status in global life sciences and pharma circles. CPI exists to facilitate and underpin those vital relationships
Sponsored by Gill Jennings & Every, By John Jappy and Ian Jones
AI is transforming the pharma industry and its drug discovery pipeline
Sponsored by Life Science Integrates, By Samuel Thangiah
UK-based company Life Science Integrates exists to facilitate collaboration between digital, pharma and life sciences industries – helping form partnerships that revolutionise healthcare
The hepatitis C drug that made waves when first launched – quicker to work and with fewer side effects than existing drugs, but it came with a hefty price tag
Source: © Shutterstock
Collaborative projects aim to produce cheaper and more effective medicines
By Ellis Wilde
Combination of Suzuki–Miyaura and Buchwald–Hartwig couplings produces carbon–nitrogen–carbon linked compounds
By Derek Lowe
Biogen abandoning Alzheimer’s antibody aducanumab is unusual, but hardly surprising, says Derek Lowe
The green transition is an opportunity to also make industry simpler and safer
By Anthony King
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
Strategy that produced new antibiotic could allow researchers to repurpose existing antibiotics
Site powered by Webvision Cloud